
A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of outcomes for acute GVHD.

A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of outcomes for acute GVHD.

Neoadjuvant relatlimab plus nivolumab showed sustained and robust activity in resectable melanoma with potential biomarkers on the horizon.

Alpha1H shows promising results in treating non-muscle-invasive bladder cancer, demonstrating significant tumor response and a strong safety profile in clinical trials.

During a live event, Steven I. Robinson, MBBS, discussed desmoid tumor statistics and management for symptomatic progression.

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data from recent clinical trials.

The FDA approves Agilent's MMR IHC Panel, enhancing personalized colorectal cancer treatment by identifying patients for targeted immunotherapy options.

New combination therapy shows promising results for advanced non-small cell lung cancer, offering hope for patients with limited treatment options.

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 diabetes compared to other treatments.

Mabwell's 7MW4911 receives FDA IND clearance, paving the way for clinical trials targeting advanced GI cancers with promising preclinical results.

A new study reveals personalized treatment strategies for HER2-negative breast cancer, optimizing antibody-drug conjugate sequencing based on tumor characteristics.

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating acute myeloid leukemia.

A groundbreaking study reveals ctDNA testing outperforms traditional imaging in predicting outcomes for patients with large B-cell lymphoma, enhancing treatment strategies.

FDA endorses bexmarilimab for higher-risk myelodysplastic syndromes, paving the way for accelerated approval and promising treatment options.

A systemic review of patient-reported outcome measures used in melanoma research and clinical practice reveals high heterogeneity and gaps in melanoma-specific validation data.

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ovarian cancer.

A groundbreaking phase 3 study for lisaftoclax offers hope for first-line treatment of higher-risk myelodysplastic syndrome, addressing a critical medical need.

FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved treatment options for patients.

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options.

New research reveals how ctDNA testing transforms treatment for muscle-invasive bladder cancer, identifying patients who benefit from targeted immunotherapy.

Neoadjuvant immunotherapy combined with chemotherapy shows promising results in treating limited-stage small cell lung cancer, enhancing surgical outcomes and survival rates.

Discover the latest breakthroughs in oncology, including FDA approvals and innovative treatments reshaping cancer care for patients and clinicians alike.

A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries.

Pembrolizumab showed strong anti-tumor activity in patients with unresectable desmoplastic melanoma.

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its potential for unmet medical needs.

FDA fast-tracks HLD-0915, a novel therapy for metastatic castration-resistant prostate cancer, promising rapid development and potential breakthrough treatment.

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ovarian cancer.

A promising allogeneic CAR T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments have failed.

New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, reducing treatment burden and side effects.

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous system involvement.

A multidisciplinary expert panel issued recommendations on the use of bronchoscopic biopsies in terms of safety and sample adequacy for comprehensive biomarker testing.